Vasopeptidase inhibition: A new treatment approach for endothelial dysfunction
- 1 May 2003
- journal article
- review article
- Published by Elsevier in Kidney International
- Vol. 63 (84) , S54-S57
- https://doi.org/10.1046/j.1523-1755.63.s84.35.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertensionAmerican Journal of Hypertension, 2002
- Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trialAmerican Journal of Hypertension, 2002
- Omapatrilat Versus LisinoprilHypertension, 2001
- Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized ratsKidney International, 2001
- Vasopeptidase Inhibition Exhibits Endothelial Protection in Salt-Induced HypertensionHypertension, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trialBritish Journal of Clinical Pharmacology, 1999
- Dual Inhibition of Neutral Endopeptidase and Angiotensin-Converting Enzyme in Rats With Hypertension and Diabetes MellitusHypertension, 1998
- Effects of Omapatrilat in Low, Normal, and High Renin Experimental HypertensionAmerican Journal of Hypertension, 1998
- Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery DiseaseCirculation, 1996